EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

Gilbert J Burckart iD, Susan M Abdel-Rahman iD, Gelareh Abulwerdi iD, Sherbet Samuels iD, Rebecca Racz iD, Mohamed A Mohamoud iD, Nicholas P Tatonetti iD

Clinical Pharmacology & Therapeutics · 2026-11 · 120 (5) · 1169-1172

DOI: 10.1002/cpt.70148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 19.11.2025. Verfasst von Gilbert J Burckart und 6 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver S…. Hauptthemen laut MEDLINE: Thalidomide, Drug Development, Child Development. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental processes. The realization of this risk comes with the understanding that we could not predict another thalidomide worldwide tragedy even 70 years later.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideDrug DevelopmentChild DevelopmentHumansChildRisk Assessment

Substanzen

Thalidomide

Autor:innen und Institutionen

  • Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.

ORCID-Profile: Gilbert J Burckart, Susan M Abdel-Rahman, Gelareh Abulwerdi, Sherbet Samuels, Rebecca Racz, Mohamed A Mohamoud, Nicholas P Tatonetti

Förderung

  • Intramural FDA HHS

Zitieren

APA

Burckart, G. J., Abdel-Rahman, S. M., Abulwerdi, G., Samuels, S., Racz, R., Mohamoud, M. A., & Tatonetti, N. P. (2026). Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?. Clinical Pharmacology & Therapeutics, 120(5), 1169-1172. https://doi.org/10.1002/cpt.70148

Vancouver

Burckart GJ, Abdel-Rahman SM, Abulwerdi G, Samuels S, Racz R, Mohamoud MA, et al. Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?. Clinical Pharmacology & Therapeutics. 2026;120(5):1169-1172. doi:10.1002/cpt.70148

BibTeX
@article{Burckart2026,
  author = {Burckart, Gilbert J and Abdel-Rahman, Susan M and Abulwerdi, Gelareh and Samuels, Sherbet and Racz, Rebecca and Mohamoud, Mohamed A and Tatonetti, Nicholas P},
  title = {Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {5},
  pages = {1169--1172},
  doi = {10.1002/cpt.70148}
}
Kostenlos starten →